In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Supernus Pharmaceuticals appears undervalued with a fair value of $65.09 versus current price $41.26, implying 57.8% upside. High valuation confidence contrasts weak profitability and efficiency scores, signaling execution risks despite strong liquidity and growth. Monte Carlo shows high volatility (CV 101.67%) and limited downside risk (11.4%), reflecting substantial return potential but elevated uncertainty.